This article is more than 5 years old. Information may no longer be current.
System to aid echocardiography receives FDA clearance
Click Here to Manage Email Alerts
Ventripoint Diagnostics announced its analysis system that works with standard echocardiography machines has been cleared for commercial use by the FDA.
The system (VMS+ 3.0 whole heart analysis system) uses a knowledge-based reconstruction technology to create 3D images of the heart and enables calculation of ejection fraction and volumes for all cardiac chambers to be as accurate as with MRI, potentially leading to less MRI use, the company stated in the release.
“We are thrilled that our innovative heart analysis system can now be used in hospitals across the United States. Millions of echocardiograms are performed in the U.S. annually and our goal is to become the premier analysis tool for cardiac imaging in both pediatric and adult hospitals,” George Adams, MD, Ventripoint’s CEO, said in the release.
Disclosure: Adams reports he is an employee of Ventripoint Diagnostics.